eXoZymes Inc. Announces Closing of $6 Million Public Offering
Rhea-AI Summary
eXoZymes (NASDAQ:EXOZ) closed a public offering of 330,575 units, including 34,440 from partial over-allotment exercise. Each unit includes two common shares and one warrant. The offering priced shares at $8.99 and warrants at $0.02, for gross proceeds of about $5.95 million.
Warrants become exercisable in one year at $11.24 per share, last five years, and are unlisted. According to eXoZymes, net proceeds will fund NCT development, additional products, R&D, working capital, and general corporate purposes.
Positive
- Gross offering proceeds of approximately $5.95 million before expenses
- Financing supports NCT development and additional product opportunities
- Funds allocated to research and development and working capital
Negative
- Issuance of new shares and warrants may dilute existing shareholders
- Warrant exercise price may reset as low as $0.001
- Unlisted warrants could create overhang without active trading market
News Market Reaction – EXOZ
In the Jun 18 session, EXOZ gained 23.70%, reflecting a significant positive market reaction. Argus tracked a peak move of +8.9% during that session. Argus tracked a trough of -10.3% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. Trading volume was elevated at 2.5x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 08 | Equity offering pricing | Negative | -3.6% | Priced unit offering of stock and warrants for about $5.33M gross. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The only prior tagged offering on Jun 8, 2026 coincided with a -3.64% move, suggesting equity offerings have previously pressured the stock.
Recent history shows eXoZymes using its Form S-3 shelf to fund NCT development and broader R&D. The Mar 31, 2026 update highlighted higher operating investment and limited cash, followed by a sequence of prospectus supplements and an offering priced on Jun 8, 2026 that led to a -3.64% reaction. Today’s closing announcement reflects continued execution of that capital-raising strategy under the same shelf.
Key Terms
underwritten public offering financial
warrant financial
over-allotment option financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
LOS ANGELES, CA / ACCESS Newswire / June 17, 2026 / eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or "Company"), a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines, today announced the closing of its previously announced underwritten public offering of common stock and warrants.
The offering consisted of 330,575 units, including 34,440 units sold in partial exercise of over-allotment option, each unit consisting of two shares of common stock and one warrant to purchase one additional share of common stock. The public offering price per share was
The warrants become exercisable one year from the date of issuance at an exercise price of
The Company intends to use net proceeds from the offering to support development and commercialization activities related to N-trans-caffeoyltyramine ("NCT"), advance additional product opportunities, fund research and development activities, and for working capital and other general corporate purposes.
MDB Capital acted as sole book-running manager for the offering. The securities described above were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-292781), which was declared effective by the U.S. Securities and Exchange Commission ("SEC") on January 23, 2026. A final prospectus supplement and accompanying prospectus describing the terms of the offering was filed with the SEC on June 8, 2026 and are available on the SEC's website at www.sec.gov.
About eXoZymes
Founded in 2019, the company has developed a biomanufacturing platform that - as a historic first - offers the tools and insights to design, engineer, control and optimize nature's own natural processes to produce highly valuable natural products, via a commercially scalable, sustainable, and abundant alternative: exozymes.
Exozymes are advanced enzymes enhanced through bioengineering and AI to thrive in a bioreactor without using living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform abundant feedstock into valuable nutraceuticals and novel medicines.
By freeing enzyme-driven chemical reactions from cellular constraints, exozyme biosolutions remove the scaling bottleneck that has impeded synthetic biology's commercial success, paving the way for exozymes to lead the next generation of biomanufacturing innovation. eXoZymes Inc. introduced "exozymes" as an open scientific concept rather than as a trademark. By offering this new nomenclature for wide industry adoption, the company aims to pioneer this next generation of cell-free biomanufacturing and establish itself as the market leader. Learn more at exozymes.com.
eXoZymes Safe Harbor
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely," "potential," or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of eXoZymes' quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the final prospectus related to the public offering that was filed with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.
eXoZymes contact
Lasse Görlitz, VP of Comms & IR
(858) 319-7135
press@exozymes.com
https://www.linkedin.com/company/exozymes
https://x.com/exozymes
https://www.youtube.com/@exozymes
SOURCE: eXoZymes
View the original press release on ACCESS Newswire